COMMUNIQUÉS West-GlobeNewswire

Assertio Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:01

Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 [...]

Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress

07/08/2024 - 22:01

Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 [...]

Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors

07/08/2024 - 22:00

CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed [...]

Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida

07/08/2024 - 16:00

ROSELAND, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a [...]

XYMOGEN XPERIENCE Dedicated Exclusively to Elevating Women’s Health

07/08/2024 - 16:00

A renowned lineup of experts will address wellness insights core to women’s health beyond hormones ORLANDO, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- XYMOGEN ® is excited to announce its XYMOGEN XPERIENCE Fall 2024 (XX [...]

Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned

07/08/2024 - 16:00

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company’s [...]

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

07/08/2024 - 15:34

CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief [...]

Groundbreaking Voice of the Patient Report for pediatric low-grade glioma (pLGG) published by Pediatric Brain Tumor Foundation

07/08/2024 - 15:30

Report documents the experiences of pLGG patients, survivors, their families, and caregivers to inform future drug development for pLGG, the most common brain tumor type in children NEW YORK, Aug. 07, 2024 (GLOBE [...]

BioVie Inc. Announces Reverse Stock Split

06/08/2024 - 22:40

Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024 CARSON CITY, Nev., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that the [...]

Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

06/08/2024 - 22:36

NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

06/08/2024 - 22:31

Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage [...]

Travere Therapeutics to Present at Upcoming Investor Conferences

06/08/2024 - 22:30

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow [...]

ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

06/08/2024 - 22:30

LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]

STERIS Announces Financial Results for Fiscal 2025 First Quarter

06/08/2024 - 22:30

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook [...]

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

06/08/2024 - 22:30

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported [...]

Cellectis publie ses résultats financiers du deuxième trimestre 2024

06/08/2024 - 22:30

Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la FDA et statut de médicament orphelin accordé par la Commission européenne à UCART22 pour le traitement de la leucémie [...]

Cellectis Provides Financial Results for the Second Quarter 2024

06/08/2024 - 22:30

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30 [...]

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06/08/2024 - 22:22

Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for [...]

Globus Medical Reports Second Quarter 2024 Results

06/08/2024 - 22:15

AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net [...]